Myelitis is a rare but well documented complication of therapeutic radiation exposure to the spinal cord and is characterized by delayed development of paresthesias, sensory changes and, in severe cases, progressive paresis and paralysis. Although accepted radiation tolerance limits for the spinal cord have successfully limited the incidence of this problem (45-50 Gy, in daily 1.8-2 Gy fractions), aggressive systemic therapy may render patients more susceptible to radiation-related neurotoxicity. We describe the case of a 38-year-old man with refractory non-Hodgkin's lymphoma who underwent matched sibling peripheral blood stem cell transplant following a conditioning regimen of cyclophosphamide (60 mg/kg × 2) and total body irradiation (120 cGy × 11). This was followed by delivery of 30.6 Gy involved-field radiation at 1.8 Gy/day to the mediastinum and left supraclavicular fossa for bulky residual tumor. Although maximum cumulative radiation dose to the spinal cord was less than 45 Gy, the patient subsequently developed progressive lower extremity weakness and MRI abnormalities of the spinal cord limited to the radiation field. This represents the second report in the literature of this unexpected complication, prompting a need to reexamine current guidelines for radiotherapy in the context of high-dose systemic treatment. Bone Marrow Transplantation (2000) 26, 1355-1359.
months of treatment and are presumed to be due to transient demyelination. 1 More serious complications usually develop 9-24 months after treatment, and are thought most likely to represent intramedullary infarction or bleeding due to vascular damage. 2 Although severe progressive myelitis is rare, it may potentially lead to catastrophic paresis and sensory loss. Intensive intravenous steroid therapy can stabilize and partially improve the process, but most neurologic deficits remain irreversible.
Radiation tolerance of the normal spinal cord has been extensively documented. [3] [4] [5] [6] Although 45-50 Gy, when given at 1.8-2 Gy/day, serves as the widely accepted dose limit, contemporary data suggest the spinal cord may be significantly more radiotolerant. A recent review from the University of Florida of 1060 cases showed a 0% incidence of myelitis with doses of 40-45 Gy, a 0.4% incidence for doses between 45 and 50 Gy, and a 0% incidence for doses greater than 50 Gy. 7 Other groups have suggested that clinically significant levels of risk are not reached until delivery of 60 Gy. 4, 8 Importantly, these data only include patients treated with radiotherapy alone. Contemporary treatment strategies increasingly rely upon the combined use of radiation and chemotherapy, which may potentiate radiation damage to the spinal cord as well as other organs. Dose-intensive myeloablative therapy regimens requiring stem cell or marrow support may be the most likely to sensitize such morbidity. We describe a patient who developed unexpected radiation myelitis following total body irradiation (TBI), allogeneic stem cell transplantation, and consolidative involved-field radiation to a cumulative dose within accepted tolerance limits of the spinal cord.
Case report
A previously healthy 38 year-old man with no history of neurologic or rheumatologic disease presented with constitutional symptoms and a large mediastinal mass. The diagnosis of stage IIA diffuse large cell lymphoma, with bulky involvement of the mediastinum and left supraclavicular fossa, was made. He achieved a partial remission with six cycles of CHOP chemotherapy. Salvage therapy with two cycles of DHAP chemotherapy 9 followed by two cycles of EPOCH 10 produced only a minor response. He then
Bone Marrow Transplantation underwent high-dose chemotherapy and total body irradiation (TBI) with matched-related allogeneic peripheral blood stem cell support. Pre-transplant studies included computerized tomography of the thorax which revealed a dominant anterior mediastinal mass (measuring 13 cm at greater diameter), residual left periclavicular disease, moderate pleural and pericardial effusions, and parenchymal involvement of the lungs and liver (Figure 1 ). Marrow examination showed no evidence of disease. The conditioning regimen consisted of cyclophosphamide (60 mg/kg × 2) and TBI (120 cGy × 11 over 4 days, utilizing dual 60 Co sources situated on either side of the patient, separated by 328.3 cm).
11 TBI was administered three times daily, with an interfraction interval of at least 6 h and a dose rate limited to between 4.75 and 5.47 cGy/min. No specific shielding to protect lungs or other organs was employed. Peripheral blood stem cell donation and administration was as previously reported. 12 Because of concern with the pleural and pericardial effusions, graft-versus-host disease (GVHD) prophylaxis was limited to cyclosporine and prednisone, as previously described. 13 For CNS prophylaxis, he received alternating intrathecal cytarabine/hydrocortisone and methotrexate in standard doses. He received a total of five such treatments, one before and four after transplant. The patient tolerated the post-transplant period well with limited mucositis, anorexia and nausea, and experienced no clinical GVHD. Computerized tomography 1 month after transplant showed complete resolution of parenchymal lung and liver abnormalities. Partial interval resolution of left supraclavicular and bilateral perihilar adenopathy, and pleural effusions was also appreciated. There was only minimal resolution of the residual anterior mediastinal mass to 11 cm at its greatest diameter.
Forty-six days after PBSC infusion, and 10 months after initial presentation, the patient began consolidation radiation therapy to the mediastinal and left supraclavicular regions. Blood counts before starting mediastinal radiation included WBC 4.7, Hct 28.6, and platelets 127 000.
Two non-contiguous fields were used. The chest was treated with an oppositional AP:PA field arrangement covering the post-transplant disease volume with tight one centimeter margins, extending from the T3 to the T9 vertebral body levels ( Figure 2 ). The left supraclavicular fossa was treated with a single anterior field angled 5°right from perpendicular, away from the spinal column ( Figure 3) . A medial corner block was also added to further protect the spinal cord. Divergence of this field inferiorly into the AP chest field was prevented by a 1 cm separation between fields on the surface of the anterior chest, and by placing a half-beam block along the inferior margin of the supraclavicular field. All fields were treated daily with 6 MV energy photons. 30.6 Gy in 17 fractions was prescribed to the midplane of the chest and to a depth of 3 cm at the supraclavicular fossa. Treatment was completed in 24 days without unplanned breaks or serious acute sequelae. Radiation port verification films were obtained weekly throughout the treatment course and confirmed proper field localization.
Detailed dosimetry confirmed that the maximum radiotherapy dose received by the thoracic portion of the spinal cord during TBI was 13.2 Gy. Doses received along the upper thoracic cord during consolidation radiotherapy ranged from a minimum of 30.6 Gy at T9, to a maximum of 31.4 Gy at T3. Scattered dose contribution from the supraclavicular field to the superior thoracic spinal cord was calculated to be less than 0.15 Gy in total. Therefore, the cumulative radiation doses received by the cord ranged from 43.8 Gy at the level of T9, to 44.75 Gy at the level of T3.
The patient initially did well following treatment, demonstrating complete resolution of mild to moderate radiation dermatitis and esophagitis within several weeks. No significant pulmonary complaints were described. Over the next 9 months, computed tomography of the chest showed complete clearing of the pleural effusions, regression of the mediastinal mass, and post-radiation interstitial lung changes within the area of the mediastinal treatment port.
However, approximately 19 months following consolidative radiotherapy, the patient experienced right-sided flank and abdominal hypesthesia. Over the ensuing month, he experienced distal right lower extremity weakness, progressing to impaired ambulation. Cerebrospinal fluid evaluation was negative for malignancy or infectious pathogens, and restaging evaluation showed no evidence for tumor relapse. Magnetic resonance imaging (MRI) showed edema of the spinal cord between T3 and T8, consistent with radiation myelitis (Figure 4 ). Post-radiation fatty marrow change within the adjacent vertebral bodies was also noted. Subsequent serial MRI studies confirmed stable enhancement in the spinal cord, without new areas of involvement.
Figure 4
Post-radiotherapy T2-weighted MRI imaging of thoracic spinal cord. Adjacent sagittal images confirm abnormal signal intensity from T3 to T5 (left, marked by arrowheads) and from T5 to T8 (right, marked by arrowheads), consistent with edema. Post-radiotherapy fatty marrow change can be seen in the adjacent vertebral bodies.
Bone Marrow Transplantation
High-dose pulse steroids induced a transient response with increased muscle strength. However, 24 months after consolidative radiotherapy the patient was paraplegic, and had lost bowel and bladder function. Courses of famciclovir and anticoagulation were given without significant benefit. At 30 months following consolidative radiation, the patient's neurologic condition remains stable, and there continues to be no evidence for disease recurrence.
Discussion
Relapse following transplantation for aggressive lymphoma frequently occurs at areas previously involved with bulky disease.
14 Consolidation of such high-risk sites with involved field radiotherapy for Hodgkin's disease patients appears in non-randomized institutional series to increase complete remission and loco-regional control rates, 15 and to lengthen freedom from relapse intervals and overall survival. 16 Although one series reported significant hematologic toxicity following consolidative radiotherapy, no adverse neurologic events specific to radiotherapy were reported. 17 Since radiation myelitis is not associated with any pathognomonic features, it can be entertained only after all infectious, metastatic, neurologic, and orthopedic etiologies have been excluded. More specifically, opportunistic leptomeningitis (varicella zoster virus, cytomegalovirus, aspergillosis, tuberculosis, bacterial), epidural or vertebral metastasis, congenital or acquired spine malformations, preexisting central nervous system damage, and intracranial/spinal infarction secondary to an auto-immune, vasculitic or hypercoagulable state must all be considered.
In our patient, there was no clinical evidence to suggest any of these causes. The patient's CSF serology and cultures revealed no abnormal findings, and confirmed no infectious pathogens. A presumptive course of famciclovir against varicella zoster virus proved unhelpful, as did a trial course of anticoagulation therapy. It is unlikely that the patient suffered a radiation or chemotherapy hypersensitivity reaction. This is due to the absence of abnormalities in the remainder of the spinal cord, which had been exposed to systemic and intrathecal chemotherapy, as well as 1320 cGy during TBI. Without evidence for disease recurrence, it is also difficult to presume a paraneoplastic etiology. This condition classically affects the entire central nervous system non-specifically. 18 MRI serves as the most useful imaging modality for radiation myelitis of recent onset. It typically reveals enhanced signal intensity on T2-weighted images and post-gadolinium T1-weighted images due to changes in water content of the spinal cord, confined to areas exposed to radiation. In the absence of competing etiologies, the specificity of these findings for radiation myelitis is considered to be adequate for diagnosis. Our patient had these findings limited to the region of cord treated by the thoracic radiotherapy fields. The patient's neurologic deficits corresponded specifically to the location of these radiologic abnormalities, and developed in a time frame consistent with a radiation-related etiology. Since antemortem histopathologic confirmation of radiation myelitis is impractical, it most often remains a diagnosis of exclusion.
A similar report 19 details a case of radiation myelitis in a non-Hodgkin's lymphoma patient suffering lower extremity paresis 3 months following delivery of 40.3 Gy in 22 fractions to a large mediastinal/supraclavicular field. That patient had previously received six cycles of VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisolone), followed by high-dose cyclophosphamide and busulphan with autologous marrow transplantation. Radiotherapy was given as consolidation to initial sites of bulky disease. Of note, that patient did not receive TBI. Radiographic findings were similar to those of our patient, with abnormalities confined to the region of the spinal cord exposed to the maximum radiation dose delivered.
TBI is considered integral to current marrow and stem cell transplantation strategies for many diseases. TBI in this case was administered with a hyperfractionated schedule utilizing a small fraction size of 120 cGy. Radiobiologic principles predict that late-responding neural tissue should better tolerate this form of therapy, compared with the standard fraction size of 1.8-2 Gy. 20 Nonetheless, previous reports have documented unexpected cases of radiation myelitis following delivery of 'accelerated' hyperfractionated radiotherapy for head and neck cancer. 21, 22 These reported cases developed following administration of 39.9-48.3 Gy to the spinal cord, given in fractions of 1-1.5 Gy up to four times daily, with interfraction times as short as 3 h. These reports suggest that incomplete radiation repair within the spinal cord between hyperfractionated treatments could lead to clinically significant morbidity. This appears to be a less significant concern in this patient's case given the 13.2 Gy total dose, 1.2 Gy fraction size, and 6 h interfraction interval of the patient's TBI regimen. Also, the intervening delay between TBI and consolidative radiation would have allowed for some degree of radiation repair in the spinal cord between the two radiotherapy courses. Prior or concurrent chemotherapy, though, may have limited this compensating effect.
Although it is difficult to ascertain the exact role of TBI in this patient's injury, the severity of the complication supports limiting exposure of the spinal cord to aggressive radiotherapy consolidation following TBI administered in large fractions or with abbreviated interfraction intervals (eg Ͻ6 h).
The systemic cytotoxic therapy received by our patient was a likely contributing factor to the observed radiation neurotoxicity. The use of intrathecal therapy may also be relevant. Intrathecal methotrexate, given alone or in combination with radiotherapy, has been closely associated with cerebral leukoencephalopathy, 23 especially in the pediatric population. 24 However, such risk is limited to 5% if systemic methotrexate is not administered. 25 Although spinal myelopathy has been observed following intrathecal methotrexate and/or cytarabine with craniospinal irradiation in children, 26 this experience is very limited and no formal association has been rigorously established. The use of intrathecal therapy in patients at risk for CNS relapse following transplant improves freedom from disease relapse within the neuroaxis 27 and is standard practice for high risk patients.
It is important to acknowledge that patients consolidated with radiation after transplant are those who are at high risk for clinical failure, and frequently have received intensive treatment prior to transplant. Although aggressive therapy should not be withheld, feasible radiotherapeutic precautions can be considered. In this patient's case, field modifications might have included a posterior spinal cord block, anterior dose weighting, or even an angled off-cord field arrangement, although this would have potentially treated greater volumes of heart and lung. It may be necessary to treat residual disease incompletely in some cases. Improved post-transplant staging (eg PET scanning) may optimize the safety of these field modifications, without compromising treatment efficacy. To conclude, commonly accepted normal tissue radiation tolerances may have limited applicability following doseintensive transplant therapy. Radiation treatment to organs not typically felt to be at high risk for toxicity, such as the spinal cord, should be carefully assessed and planned. It is important to properly counsel patients regarding the attendant neurologic risks of radiotherapy consolidation following transplantation.
